Nabriva Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Nabriva Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Nabriva Therapeutics: 6 sponsored US clinical trials, none currently recruiting.
Nabriva Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Community-acquired Pneumonia, with 1 trials.
Upper-quartile sponsor footprint
Nabriva Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
NCT05225805
4-way Crossover QT Evaluation in Healthy Subjects
NCT03709927
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
NCT02813694
Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
NCT02753946
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
NCT02559310
Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
NCT01119105
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
How the Nabriva Therapeutics early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).
Phase mix: 2 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Community-acquired Pneumonia (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Nabriva Therapeutics: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Nabriva Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Nabriva Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Nabriva Therapeutics or any single study.
- None of Nabriva Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Community-acquired Pneumonia is the condition Nabriva Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Community-acquired Pneumonia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Nabriva Therapeutics pipeline card: 6 registered trials from official public datasets.Report a data error.